TY - JOUR T1 - Long-term clearance of hepatitis C virus following interferon alpha-2b or peginterferon alpha-2b, alone or in combination with ribavirin JF - J Viral Hepat Y1 - 2013 A1 - Manns, M.P. A1 - Pockros, P.J. A1 - Norkrans, G. A1 - Smith, C.I. A1 - Morgan, T.R. A1 - Haussinger, D. A1 - Shiffman, M.L. A1 - Hadziyannis, S.J. A1 - Schmidt, W.N. A1 - Ira M. Jacobson A1 - Barcena, R. A1 - E R Schiff A1 - Shaikh, O.S. A1 - Bacon, B. A1 - P. Marcellin A1 - Deng, W. A1 - Esteban-Mur, R. A1 - Poynard, T. A1 - Pedicone, L.D. A1 - Brass, C.A. A1 - Albrecht, J.K. A1 - Gordon, S.C. KW - blood KW - clinical trial KW - drug therapy KW - Drug Therapy,Combination KW - Follow-Up Studies KW - Germany KW - HCV KW - Hepacivirus KW - hepatitis KW - Hepatitis C KW - hepatitis C virus KW - Hepatitis C,Chronic KW - Humans KW - interferon KW - Interferon Alfa-2b KW - Interferon-alpha KW - isolation & purification KW - Multicenter Studies KW - Patients KW - peginterferon KW - peginterferon alfa-2b KW - Polyethylene Glycols KW - Prospective Studies KW - Proteins KW - Recombinant Proteins KW - Recurrence KW - Research KW - Research Support KW - Ribavirin KW - Rna KW - Rna,Viral KW - Serum KW - sustained virologic response KW - SVR KW - therapeutic use KW - therapy KW - treatment KW - Treatment Outcome VL - 20 SP - 524-529 IS - 8 ER -